Companies Compass Therapeutics, Inc.
Compass Therapeutics (CMPX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Compass Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $4,873,206FY2023
- $3,093,057FY2024
- $5,097,150FY2025
CEO total pay was $5,097,150 in fiscal 2025, up from $3,093,057 in fiscal 2024.
FY2025: salary $630,000 · bonus $381,150 · stock awards $0 · option awards $4,065,000
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Thomas Schuetz | $630,000 | $381,150 | $0 | $4,065,000 | $0 | $0 | $21,000 | $5,097,150 |
| Chief Executive Officer | ||||||||
| Jonathan Anderman | 450,000 | 198,000 | 0 | 758,800 | — | — | 0 | 1,427,800 |
| General Counsel and Corporate Secretary | ||||||||
| Barry Shin | 480,000 | 216,000 | 0 | 677,500 | 0 | 0 | 21,000 | 1,394,500 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Thomas Schuetz | $5,097,150 | $3,093,057 | $4,873,206 | ↑ +2,004,093 |
| Jonathan Anderman | 1,427,800 | 893,635 | — | ↑ +534,165 |
| Barry Shin | 1,394,500 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Compensation is designed to enable the company to attract and retain talented and experienced executives to lead successfully in a competitive environment. The company targets being competitive to peer companies and utilizes independent, third-party benchmarking and analytics to inform the level and mix of base salary, annual bonus, and long-term equity incentives.
| CEO STI target (% of salary) | NaN% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | The company has adopted an incentive compensation recoupment policy applicable to executive officers. If financial results must be restated to correct an accounting error due to material noncompliance, the company will seek to recover excess incentive-based compensation received by covered officers during the three completed fiscal years preceding the restatement date. |
| Anti-hedging | The insider trading policy expressly prohibits short sales and derivative transactions of company stock by executive officers, directors, employees, and certain designated consultants and contractors. It also prohibits, without advance approval of the Audit Committee, purchases or sales of puts, calls, or other derivative securities. |
| Anti-pledging | The proxy statement notes that securities held in a margin account or pledged as collateral create heightened compliance risk, but does not explicitly state a blanket prohibition on pledging in the policy description, only that the policy is designed to promote compliance and address these risks. |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jonathan Anderman | Option | 2,068 | 2.4 | — |
| Jonathan Anderman | Option | 23,322 | 3.93 | — |
| Thomas Schuetz | Option | 29,136 | 2.4 | — |
| Jonathan Anderman | Option | 43,326 | 1.57 | — |
| Barry Shin | Option | 197,910 | 3.65 | — |
| Jonathan Anderman | Option | 200,000 | 1.2 | — |
| Thomas Schuetz | Option | 204,144 | 3.93 | — |
| Jonathan Anderman | Option | 221,660 | 3.65 | — |
| Thomas Schuetz | RSU | 250,000 | — | 1,342,500 |
| Barry Shin | RSU | 300,000 | — | 1,611,000 |
| Barry Shin | Option | 300,000 | 1.65 | — |
| Thomas Schuetz | Option | 332,037 | 1.93 | — |
| Thomas Schuetz | RSU | 478,125 | — | 2,567,531 |
| Thomas Schuetz | Option | 1,187,500 | 3.65 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Carl L. GordonIndependent · Compensation (Chair) | $65,000 | $0 | $108,400 | — | $0 | $173,400 |
| Ellen V. ChiniaraIndependent · Audit · Nominating and Corporate Governance | 60,000 | 0 | 108,400 | — | 0 | 168,400 |
| Philip J. FerneauIndependent · Nominating and Corporate Governance (Chair) · Compensation | 55,000 | 0 | 108,400 | — | 0 | 163,400 |
| Richard S. LindahlIndependent · Audit (Chair) | 55,000 | 0 | 108,400 | — | 0 | 163,400 |
| James P. BoylanIndependent · Audit | 50,000 | 0 | 108,400 | — | 0 | 158,400 |
| Mary Ann GrayIndependent · Compensation | 45,000 | 0 | 108,400 | — | 0 | 153,400 |
| Thomas J. SchuetzEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $330,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $330,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Compass Therapeutics as a peer
Companies that benchmark against CMPX
4 companies name CMPX as a compensation peer
- Definium Therapeutics, Inc.DFTXFY2025
- NEKTAR THERAPEUTICSNKTRFY2025
- SELLAS Life Sciences Group, Inc.SLSFY2025
- Verastem, Inc.VSTMFY2025
Each company listed discloses CMPX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CMPX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Compass Therapeutics, Inc. | 2025 | Thomas Schuetz | $630,000 | $0 | $4,065,000 | $0 | $5,097,150 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-10 | 117,963,684 | 1,796,022 | 2,061,977 | 98.5% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-10 | 98.5%a |
a. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (14 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Thomas Schuetz. DEF 14A, filed 2026-04-29. Section “Executive Compensation” · page 21. As printed: 5,097,150. View filing ↗
- Section 01, Jonathan Anderman. DEF 14A, filed 2026-04-29. Section “Executive Compensation”. As printed: 1,427,800. View filing ↗
- Section 01, Barry Shin. DEF 14A, filed 2026-04-29. Section “Executive Compensation”. As printed: 1,394,500. View filing ↗
- Section 08, Carl L. Gordon. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 173,400. View filing ↗
- Section 08, Ellen V. Chiniara. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 168,400. View filing ↗
- Section 08, Philip J. Ferneau. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 163,400. View filing ↗
- Section 08, Richard S. Lindahl. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 163,400. View filing ↗
- Section 08, James P. Boylan. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 158,400. View filing ↗
- Section 08, Mary Ann Gray. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 153,400. View filing ↗
- Section 08, Thomas J. Schuetz. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-11. Item 5.07 · say-on-pay result. As reported: 98.5% (votes for as printed: 117,963,684). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 330,000 + equity 0 + all other 0 = 330,000, summed across the director compensation table rows.
- Compass Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Compass Therapeutics, Inc.'s own proxy. As printed: 5,097,150. View filing ↗